Wednesday, 16 Jan 2019

You are here

EULAR 2018 - Day 3 Report

Behcet’s Responds to Apremilast – We missed reporting this one on Wednesday when Hatemi et al presented the results of a phase 3 trial of apremilast (APR) vs placebo (PBO) in active Behcet’s with oral ulcers, with ≥3 OU at the start. BD patients (n-207) were randomized (1:1) to APR 30 mg BID or PBO (n=103) for 12 weeks, followed by a 52-week active-treatment extension.  The total number of Oral Ulcers was statistically significantly lower in the APR group compared with the PBO group. Numerically greater number of patients had resolution of genital ulcers at Week 12 in the APR group.  It appears this drug is headed to the FDA for decision later this year.

Biologics Do Not Differentially Affect TKR/THR Post-Operative Infection Rates  – a review of the claims data looked at over 11,000 RA patients on biologics (Abatacept, Adalimumab, Etanercept, Infliximab and fewer on Rituximab or Tocilizumab). (OP0228). The post-op hospitalized infection rate was 6.6 to 8.5% and was not significant between biologics (similar for the 30 day readmission rate). This was clearly different with steroid use which showed a dose related increased risk of hospitalized infection and 30 day readmission for infection, with a 2 fold increase risk for those receiving prednisone > 10 mg per day.  Similarly prosthetic joint infections were increased with increasing steroid use but were similar in frequency with biologics. Tocilizumab was associated with a higher risk of prosthetic infections, but this finding is less certain given the lower, limited number of TCZ treated patients in this cohort. (Correction: this article has been updated to reflect the correct abstract, OP0228. We apologize for any inconvenience.)

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Price of Drug Promotion Skyrockets

JAMA reports that health care advertising costs in the U.S. have almost doubled over the past two decades, surging from $17.7 billion in 1997 to at least $29.9 billion in 2016. (Citation source: https://buff.ly/2Rk8a9Q)

2018 Rheumatology Year In Review

This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review.  The top 10 list herein is rooted in what rheumatologists should know and what will likely change their standards and practice in the future, if not 2019. 

Best of 2018: Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Best of 2018: Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.

Rising Physician Exclusion from Medicare and Medicaid

JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance. 

Overall the authors found that the number of physicians excluded from Medicare, Medicaid, and other state public insurance programs increased on average by 20% per year between 2007 and 2017.